Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium.
Division of Gastroenterology, Rabin Medical Center, Beilinson Hospital, Petach Tikwa, Israel and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Neurogastroenterol Motil. 2021 Aug;33(8):e14237. doi: 10.1111/nmo.14237.
Gastroparesis is a condition characterized by epigastric symptoms and delayed gastric emptying (GE) rate in the absence of any mechanical obstruction. The condition is challenging in clinical practice by the lack of guidance concerning diagnosis and management of gastroparesis.
A Delphi consensus was undertaken by 40 experts from 19 European countries who conducted a literature summary and voting process on 89 statements. Quality of evidence was evaluated using grading of recommendations assessment, development, and evaluation criteria. Consensus (defined as ≥80% agreement) was reached for 25 statements.
The European consensus defined gastroparesis as the presence of symptoms associated with delayed GE in the absence of mechanical obstruction. Nausea and vomiting were identified as cardinal symptoms, with often coexisting postprandial distress syndrome symptoms of dyspepsia. The true epidemiology of gastroparesis is not known in detail, but diabetes, gastric surgery, certain neurological and connective tissue diseases, and the use of certain drugs recognized as risk factors. While the panel agreed that severely impaired gastric motor function is present in these patients, there was no consensus on underlying pathophysiology. The panel agreed that an upper endoscopy and a GE test are required for diagnosis. Only dietary therapy, dopamine-2 antagonists and 5-HT receptor agonists were considered appropriate therapies, in addition to nutritional support in case of severe weight loss. No consensus was reached on the use of proton pump inhibitors, other classes of antiemetics or prokinetics, neuromodulators, complimentary, psychological, or more invasive therapies. Finally, there was consensus that gastroparesis adversely impacts on quality of life and healthcare costs and that the long-term prognosis of gastroparesis depends on the cause.
A multinational group of European experts summarized the current state of consensus on definition, symptom characteristics, pathophysiology, diagnosis, and management of gastroparesis.
胃轻瘫是一种以胃排空延迟为特征的疾病,在不存在任何机械性梗阻的情况下会出现上腹痛症状。由于缺乏胃轻瘫的诊断和治疗指南,该疾病在临床实践中极具挑战性。
来自 19 个欧洲国家的 40 名专家采用 Delphi 共识法,对 89 项陈述进行文献综述和投票。使用推荐评估、制定和评估标准对证据质量进行评估。对于 25 项陈述达成了共识(定义为≥80%的一致性)。
欧洲共识将胃轻瘫定义为存在与胃排空延迟相关的症状,且不存在机械性梗阻。恶心和呕吐被确定为主要症状,常伴有餐后不适综合征的消化不良症状。胃轻瘫的确切流行病学尚未详细了解,但糖尿病、胃手术、某些神经和结缔组织疾病以及某些被认为是危险因素的药物的使用。虽然专家组一致认为这些患者存在严重受损的胃动力功能,但对潜在的病理生理学没有达成共识。专家组一致认为,上消化道内镜和胃排空检查是诊断所必需的。除了在严重体重减轻的情况下进行营养支持外,仅饮食治疗、多巴胺 2 拮抗剂和 5-HT 受体激动剂被认为是合适的治疗方法。对于质子泵抑制剂、其他类别的止吐药或促动力药、神经调节剂、补充剂、心理治疗或更具侵袭性的治疗方法,专家组没有达成共识。最后,专家组一致认为胃轻瘫会对生活质量和医疗保健成本产生不利影响,并且胃轻瘫的长期预后取决于病因。
一组来自欧洲的多国专家总结了目前对胃轻瘫定义、症状特征、病理生理学、诊断和治疗的共识状态。